Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.89
+0.18 (1.54%)
Aug 21, 2026, 3:50 PM EDT - Market open
Kura Oncology Revenue
Kura Oncology had revenue of $20.87M in the quarter ending June 30, 2026, with 36.54% growth. This brings the company's revenue in the last twelve months to $77.23M, down -7.27% year-over-year. In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth.
Revenue (ttm)
$77.23M
Revenue Growth
-7.27%
P/S Ratio
13.89
Revenue / Employee
$297,019
Employees
260
Market Cap
1.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.48M | 13.60M | 25.24% |
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 204.56M |
| Wave Life Sciences | 65.37M |
| Lexicon Pharmaceuticals | 41.47M |
| Janux Therapeutics | 24.00M |
| Inventiva | 7.94M |
| Attovia Therapeutics | 1.35M |
| Odyssey Therapeutics | 99.00K |
| Avalo Therapeutics | 59.00K |
KURA News
- 3 days ago - Kura Oncology CEO buys $1.11M in common stock - TheFly
- 4 days ago - Kura Oncology reports Q2 EPS (77c), consensus (88c) - TheFly
- 4 days ago - Kura Oncology price target raised to $31 from $30 at BofA - TheFly
- 8 days ago - Kura Oncology Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Kura Oncology Earnings release: Q2 2026 - Filings
- 8 days ago - Kura Oncology Quarterly report: Q2 2026 - Filings
- 8 days ago - Kura Oncology Slides: Q2 2026 - Filings
- 8 days ago - Kura Oncology Reports Second Quarter 2026 Financial Results - GlobeNewsWire